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René Reinert, Matthias Imöhl
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Abstract
This study presents serogroup 6 isolates from invasive pneumococcal disease (IPD) before and after the recommendation
for childhood pneumococcal conjugate vaccination in Germany (July 2006). A total of 19,299 (children: 3508, adults: 15,791)
isolates were serotyped. Serogroup 6 isolates accounted for 9.5% (children) and 6.7% (adults), respectively. 548 isolates had
serotype 6A, 558 had serotype 6B, 285 had serotype 6C, and 4 had serotype 6D. Among children, serotype 6B was most
prevalent (7.5% of isolates) before vaccination, followed by 6A and 6C. After the 7-valent pneumococcal conjugate vaccine
(PCV7), the prevalence of serotype 6B significantly decreased (p = 0.040), a pattern which continued in the higher-valent PCV
period (PCV10, PCV13). Serotype 6A prevalence showed a slight increase directly after the start of PCV7 vaccination,
followed by a decrease which continued throughout the PCV10/13 period. Serotype 6C prevalence remained low. Serotype
6D was not found among IPD isolates from children. Among adults, prevalence of both 6A and 6B decreased, with 6B
reaching statistical significance (p = 0.045) and 6A showing a small increase in 2011–2012. Serotype 6C prevalence was 1.5%
or lower before vaccination, but increased post-vaccination to 3.6% in 2011/12 (p = 0.031). Four serotype 6D isolates were
found post-PCV7 childhood vaccination, and two post-PCV10/13. Antibiotic resistance was found mainly in serotype 6B;
serotype 6A showed lower resistance rates. Serotype 6C isolates only showed resistance among adults; serotype 6D isolates
showed no resistance. Multilocus sequence typing showed that sequence type (ST) 1692 was the most prevalent serotype
6C clone. Thirty-two other STs were found among serotype 6C isolates, of which 12 have not been previously reported. The
four serotype 6D isolates had ST 948, ST 2185 and two new STs: 8422 and 8442. Two serogroup 6 isolates could not be
assigned to a serotype, but had STs common to serogroup 6.
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Introduction
Streptococcus pneumoniae remains a major cause of infectious
disease globally, especially in children. Invasive pneumococcal
disease (IPD) causes an estimated 0.5 million deaths among
children worldwide [1]. The most important virulence factor of S.
pneumoniae is the polysaccharide capsule. Currently, 94 capsular
types, or serotypes, have been described.
Before the introduction of pneumococcal conjugate vaccination,
serogroup 6 was one of the most common causes of IPD among
childrenandadults.Originally, serogroup6comprisedtwoserotypes,
6A and 6B. Using monoclonal antibodies, a new serotype, serotype
6C, could be identified among isolates previously typed as 6A. In
serotype 6C, the capsular locus of the wciNa gene has been replaced
through homologous recombination by the wciNb gene [2]. By
cloning the wciNb gene into a 6B strain, the possibility of yet another
subtype, serotype 6D, was proven in a lab environment [3]. Shortly
after that, serotype 6Dwas found in clinical isolates [4–6].Currently,
serogroup 6 contains four serotypes, with serotype 6A having the
wciPageneandthewciNagene,6B(wciPb,wciNa),6C(wciPa,wciNb) and
6D (wciPb, wciNb) [7].
Some serotype 6A and 6B isolates contain a 300 bp long
insertion between the wciO and the wciN gene. Based on the
presence of this INDEL sequence, the gene loci are divided into
class I (with INDEL) and class II (without INDEL) sequences. The
majority of 6A and 6B isolates do not carry an INDEL and belong
to class I [7].
Since 2001, a pneumococcal conjugate vaccine (PCV7) has
been available, covering the seven serotypes most prevalent in
invasive pneumococcal disease (4, 6B, 9V, 14, 18C, 19F and 23F).
After introduction of this vaccine in the US, a strong reduction of
the incidence of vaccine-type IPD has been observed [8]. PCV7
includes serotype 6B. It was suggested, on the basis of antibody
ELISA and opsonophagocytosis tests, that PCV7 elicits some level
of cross-protection to serotype 6A [9]. In a study from the US, it
was shown that this was indeed the case, since the incidence of
serotype 6A decreased after introduction of the vaccine [10,11].
However, PCV7 does not provide cross-protection to serotype 6C,
and an increase in serotype 6C was observed in the US after
introduction of PCV7 [11].
In 2009, higher-valent pneumococcal conjugate vaccines were
licensed in Germany. A 10-valent vaccine (PCV10) contains the
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PCV7 serotypes, plus serotypes 1, 5 and 7F, and a 13-valent
vaccine (PCV13) is comprised of serotypes 3, 6A and 19A in
addition to the PCV10 serotypes. For PCV13, a cross-protection
from serotype 6A antibodies for serotype 6C was speculated,
because PCV13 immune sera showed strong opsonophagocytic
responses to serotype 6C [12]. In a study on children with acute
otitis media in France, Cohen et al. showed that in PCV13-
vaccinated children, carriage of serotype 6C was significantly
reduced as compared to PCV7-vaccinated children [13].
In Germany, a general recommendation for pneumococcal
conjugate vaccination for all children under two years of age was
issued in July 2006. Initially, vaccination was performed with
PCV7. Beginning in 2009, with the licensing of higher-valent
vaccine formulations, PCV10 was used in vaccinations from April
of that year, and PCV13, which replaced PCV7, was introduced in
December 2009. The aim of this study was to determine the effects
of this vaccination recommendation on invasive pneumococcal
disease caused by serogroup 6. Furthermore, we aimed to
determine the presence of serotypes 6C and 6D among invasive
isolates from both adults and children, and to verify their role in
the epidemiology of serogroup 6 IPD after the start of vaccination.
Materials and Methods
Study Material
Serogroup 6 isolates were obtained from ongoing surveillance
studies on IPD in children in Germany under 16 years of age from
July 1997 to June 2012 [14] and from adults 16 years and older
from July 1992 to June 2012 [15]. S. pneumoniae samples isolated
from blood, CSF or other normally sterile body sites were included
in the study. Cases of IPD were grouped per pneumococcal season
(from July in one year til June in the following year), since
infections tend to cluster around the winter months.
Serotyping
All pneumococcal isolates were serotyped using the Neufeld’s
Quellung reaction with group and factor sera provided by the
Statens Serum Institut, Copenhagen, Denmark. All serotype 6A
and 6B isolates were revived from frozen stocks and retested for
serotypes 6C and 6D. Initially, 6A isolates were tested for 6C using
the PCR method described by Park [2]. As new factor sera 6b, 6c
and 6d became available from the Statens Serum Institut, these
were used for analysis, with serotype 6A testing positive for factor
serum 6b, serotype 6B testing positive for factor serum 6c and
serotype 6C testing positive for factor serum 6d. Serotype 6B
isolates were tested with sera only. Isolates positive for 6D (reacting
with factor sera 6b and 6d) were verified with several PCRs using
primers described by Jin et al. [16]. Using a random number
generator in MS-Excel, a sampling of serotype 6A and 6B isolates
were selected and tested for the presence of the INDEL sequence
between the wciN and wciO genes [7,17] using the same primers as
described above [2].
Susceptibility Testing
All isolates were tested for antibiotic minimal inhibitory
concentrations (MIC) using the broth microdilution method as
recommended by the Clinical and Laboratory Standards Institute
(CLSI) [18]. The microtiter plates (Sensititre NLMMCS10,
TREK Diagnostic Systems Ltd., East Grinstead, UK) contained
penicillin G, clarithromycin (erythromycin before 2004 and after
2011), clindamycin and tetracycline with cation adjusted Mueller-
Hinton broth (Oxoid, Wesel, Germany) and 5% lysed horse blood.
The final inoculum was 56105 CFU/ml. Incubation was at 37uC
for 24 h in ambient air. S. pneumoniae ATCC 49619 was used as
a control strain. For interpretation, the current CLSI criteria were
applied [18]. For penicillin susceptibility, the ‘oral’ breakpoints
were used (#0.06 mg/ml, 0.12–1 mg/ml, $2 mg/ml), since they
provide better insight into resistance development over time.
Multilocus Sequence Typing
Multilocus sequence typing of selected serogroup 6 isolates was
performed as described previously [19]. Briefly, internal fragments
of the aroE, gdh, gki, recP, spi, xpt and ddl genes were amplified by
PCR from chromosomal DNA with the described primer pairs. A
special allelic profile was provided by the alleles at each of the
seven loci and their sequence type (ST) was defined. The allelic
profiles were compared with each other and with other isolates in
the pneumococcal MLST database using software available at
www.mlst.net. Clusters of related STs were grouped into clonal
complexes (CCs) using the program eBURST (www.mlst.net).
Statistical Methods
Statistics were performed using the ’Analysis Toolpak’ in MS-
Excel. To compare the serotype prevalences before and after the
introduction of PCV7 vaccination, the two-sample t-Test assuming
equal variances was used. Results were considered significant
when p,0.05.
Results
A total of 3508 isolates from invasive pneumococcal disease
(IPD) in children (collection period: July 1997 til June 2012) and
16,109 from IPD in adults (collection period: July 1992 til June
2012) were sent to the German National Reference Center for
Streptococci for typing.
Among IPD in children, isolate numbers varied from 152 in
1998/99 to 295 in 2006/07. The average number of isolates per
pneumococcal season was 234. All 3508 isolates were serotyped.
Among adults, isolate numbers varied from 172 in 1996/1997 to
2301 in 2010/11 (average: 805). In the years 1992–1996, the
numbers of collected isolates were considerably lower. In January
2007, an enhanced, web-based reporting system (Pneumoweb) was
installed, which increased the number of reported isolates
considerably (Table 1). Previously, we have reported that in the
years before 2004, not all adult IPD isolates had been serotyped
[20]. We have now been able to type most of these not-typed
isolates, resulting in 15,791 serotyped isolates and an overall
serotyping rate of 98% (80–100%).
A total of 834 serotype 6A isolates were retested for serotype 6C
using either PCR or factor serum 6d. 546 were retyped as 6A; 285
as 6C. Two 6A isolates could not be recovered, and one 6A isolate
yielded ambiguous results. 563 6B isolates were retested, resulting
in 548 6B and four 6D isolates. Ten 6B isolates could not be
recovered for retesting, and for one 6B isolate, subtyping was
ambiguous. In further calculations, the non-recoverable isolates
were treated as having their original serotypes (6A and 6B). The
two ambiguous isolates were taken out of the serotype distribution
analysis.
A subset of 95 serotype 6B and 47 serotype 6A isolates was
tested for the presence of the INDEL described by Mavroidi [7]
and Jin [16]. The INDEL was found in 44 (46%) of the serotype
6B isolates but in none of the serotype 6A isolates.
Among children, serotype 6B was most prevalent before the
introduction of pneumococcal conjugate vaccination, followed by
serotype 6A. After the start of PCV7 vaccination, both the
percentage as well as the absolute numbers of isolates of serotype
6B strongly decreased. The decrease continued in the higher-
valent PCV period. When comparing the pre-vaccination period
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(1997–2006) with the post vaccination period (2006–2012), the
decrease reached statistical significance (p= 0.040). Serotype 6A
prevalence showed a slight increase in the first two years after the
start of PCV7 vaccination, followed by a decrease which started in
2009/2010 and continued in the PCV10/13 period. Absolute
numbers varied between 1 and 12 isolates per season over the
years, decreasing from 12 in 2008/09 to 1 in 2010/11. An increase
was observed in 2011–2012, with 5 cases. Three cases were from
non-vaccinated children, one from a 4-month-old child that got
infected 4 days after the first PCV10 vaccination, and for one case
vaccination data could not be obtained. Serotype 6C prevalence
remained extremely low, with isolate numbers varying from 0 to 3
per season. Serotype 6D was not found among isolates from
children (Table 1, Figure 1).
Among adults, serotypes 6A and 6B showed similar prevalences
in the earlier years of the study. 6B showed a diminishing trend
until 1999–2000, with a strong increase in the following season.
After the start of childhood vaccination, prevalences of both 6A
Figure 1. Prevalence of serogroup 6 serotypes over time among isolates from IPD among German children (top) and adults
(bottom).
doi:10.1371/journal.pone.0060848.g001
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and 6B decreased, with 6A showing a small increase in 2011–
2012. The decrease in serotype 6B was statistically significant, with
p= 0.045. Serotype 6C prevalence fluctuated between 0.0 and
1.5% before vaccination, with case numbers varying between 0 and
3 per season, but after vaccination increased to 3.6% (75 cases) in
2011/12. The increase was statistically significant (p = 0.031).
Serotype 6D was found in four cases, the oldest one dating from
July 2007 (Table 1, Figure 1). Isolates were from blood (3) and
pleural fluid (1). Data on diagnoses were not available. Patient ages
were 48, 61, 75 and 76 years.
Minimal inhibitory concentration analysis showed that for both
children and adults the burden of resistance was found among the
serotype 6B isolates, with a penicillin non-susceptibility of 15.2%
among children (adults 17.8%), macrolides 27.9% (31.1%),
clindamycin 21.6% (25.7%), and tetracycline 22.5% (26.6%).
Resistance levels among serotype 6A isolates were considerably
lower for isolates from both children and adults (penicillin 4.3%
(4.9%), macrolides 8.6% (10.2%), clindamycin 1.7% (3.0%), and
tetracycline 4.3% (5.8%)). Resistance levels among serotype 6C
from adults (penicillin 6.3%, macrolides 6.3%, clindamycin 3.7%,
and tetracycline 4.8%) were comparable to the levels found for
serotype 6A, although, following the vaccination period, there
were statistically-significant changes in the rate of clarithromycin-
and clindamycin- resistant in 6C isolates (p = 0.00026 and
p= 0.0025, respectively). The larger part of the resistant 6B
isolates were multi drug resistant (MDR; children 64.4%, adults
Figure 2. Percentage of resistant serotype 6B isolates from IPD among German children (top) and adults (bottom). PEN: penicillin
(breakpoints S, I, R (mg/ml ): #0.06, 0.12–1, $2), CLA: clarithromycin (breakpoints S, I, R (mg/ml ): #0.25, 0.5, $1), CLI: clindamycin(breakpoints S, I, R
(mg/ml ): #0.25, 0.5, $1), TET: tetracycline (breakpoints S, I, R (mg/ml ): #2, 4, $8).
doi:10.1371/journal.pone.0060848.g002
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65.6%), i.e. resistant to more than two different classes of
antibiotics. For 6A (children 15.4%, adults 12.5%) and 6C (adults
33.3%) isolates, these percentages were lower. Among serotype 6C
isolates from children and 6D isolates from adults, no antibiotic
resistant isolates were found (Table 2, Figure 2).
The two serogroup 6 isolates that could not be assigned to
a serotype using factor sera were studied in more detail. The 6B/
6D isolate reacted positively to factor sera 6c and 6d, which
serologically identified it as serotype 6D. PCR analysis was positive
for the wciPb and wciNa, characteristic for serotype 6B. An INDEL
sequence could not be detected. The sequence type of the isolate
was 176, an ST associated with 6A, 6B and 6C in the MLST
database (www.mlst.net). The 6A/6C isolate was positive for factor
sera 6b and 6d, which makes exact serological typing impossible,
since 6b is specific for serotype 6A and 6d is specific for serotype
6C. PCR analysis was positive for wciPa and wciNa, which is
characteristic for serotype 6A. An INDEL sequence was not
detected. The isolate had ST 681, associated with serotypes 6A
and 6C, but not with 6B in the database (Table 3).
Apart from the two isolates that gave ambiguous serotyping
results, MLST was performed on 172 other serogroup 6 isolates
(6A: 30, 6B: 78, 6C: 60, 6D: 4). This included all serotype 6C
isolates from children, and 45 out of 270 6C isolates from adults,
and all 4 6D isolates from adults. ST 1692 was the most prevalent
serotype 6C clone among both children (n= 9) and adults (n = 11).
For serotype 6C isolates, 32 other STs were found, of which 12
had not been reported before for serotype 6C (www.mlst.net). The
four serotype 6D isolates had ST 948, ST 2185 and two new STs:
8422 and 8442 (Table 4). Three 6B isolates with an INDEL for
which MLST was performed showed ST 273 (n= 2) and ST 176.
Both STs also appear in serogroup 6 isolates without an INDEL.
eBURST analysis on all 174 serogroup 6 isolates revealed three
clonal complexes (CCs), in which three serogroup 6 serotypes were
represented, and 6 CCs with two serogroup 6 serotypes. In 15 CCs
only one representative was found; four STs were singletons
(Fig. 3).
Discussion
A general recommendation for childhood pneumococcal
conjugate vaccination was issued in Germany in July 2006. In
this paper we evaluated the effects of this vaccination recommen-
dation on invasive pneumococcal disease caused by serogroup 6.
We also determined the prevalence of the two new serotypes, 6C
and 6D, among isolates from IPD in Germany.
Until the introduction of childhood conjugate vaccination in
2006, serogroup 6 isolates have always played an important role in
IPD among children in Germany, with percentages of serotype 6B
varying between 3.9 and 10.8%, and serotype 6A between 2.4 and
4.6% of all isolates.
The amount of serotype 6C isolates has always been very low
(1–3 isolates per season). After the introduction of childhood
conjugate vaccination with PCV7, a decrease in serotype 6B,
starting in 2008–2009, was observed. A year later, in 2009–2010,
serotype 6A also started to decrease, most probably due to cross-
protection from serotype 6B antibodies [9–11]. The sudden
increase in serotype 6A in 2011–2012, was due to 5 cases, of which
3 were unvaccinated children. One child was vaccinated with one
primary dose only 4 days before infection, which is too short
a period to develop immunological protection. For one child,
vaccination data could not be obtained. The sudden increase in
serotype 6A therefore emphasizes the importance of timely
vaccination. Levels of serotype 6C remained unchanged and very
low, and do not allow for conclusions on cross protection from any
conjugate vaccine.
Among isolates from IPD in adults, serotypes 6A (1.9–6.1%)
and 6B (1.0–7.7%) have played an equally important role. After
the start of childhood PCV7-vaccination, a reduction in serotype
6B IPD cases was also observed in adults. The reduction started in
2007–2008, continued until 2011–2012, and is most likely due to
herd protection effects, which are apparently of similar strength for
all three PCVs. After PCV7 childhood vaccination, serotype 6A
levels started to decrease in 2007–2008 and leveled off in 2009–
2010. The introduction of higher-valent vaccination in children
caused another strong decrease in 2010–2011, which again leveled
off in 2011–2012. This seems to indicate a stronger protective
effect from the higher-valent PCVs, and seems to be in line with
Table 2. Antibiotic resistance levels of serogroup 6 isolates
from IPD among German children and adults.
serotype n= PEN I+R (%)CLA R (%)
CLI R




6A 116 5 (4.3) 10 (8.6) 2 (1.7) 5 (4.3) 2 (1.7)
6B 204 31 (15.2) 57 (27.9) 44 (21.6) 46 (22.5) 42 (20.6)
6C 15 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
SG6 335 38 (11.3) 67 (20.0) 46 (13.7) 51 (15.2) 44 (13.1%)
all
serotypes
3508 257 (7.3) 755 (21.5) 217 (6.2) 280 (8.0) 190 (5.4%)
adults
6A 432 21 (4.9) 44 (10.2) 13 (3.0) 25 (5.8) 10 (2.3)
6B 354 63 (17.8) 110 (31.1) 91 (25.7) 94 (26.6) 87 (24.6)
6C 270 17 (6.3) 17 (6.3) 10 (3.7) 13 (4.8) 10 (3.7)
6D 4 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)




15791 953 (6.0) 1857 (11.8) 784 (5.0) 1098 (7.0) 714 (4.5%)
PEN: penicillin (breakpoints S, I, R (mg/ml ): #0.06, 0.12–1, $2), CLA:
clarithromycin (breakpoints S, I, R (mg/ml ): #0.25, 0.5, $1), CLI: clindamycin
(breakpoints S, I, R (mg/ml ): #0.25, 0.5, $1), TET: tetracycline (breakpoints S, I, R
(mg/ml ): #2, 4, $8), MDR: multi drug resistant (resistant to $3 classes of
antibiotics).
doi:10.1371/journal.pone.0060848.t002
Table 3. Characteristic of two serogroup 6 isolates which could not be unambiguously assigned to any of the four serotypes.
Isolate Serotype MLST aroE gdh gki recP spi xpt ddl Factor sera wciP wciN INDEL
PS 6657 6B or 6D 176 7 13 8 6 10 6 14 6c +, 6d + wciPb wciNa no
PS 16864 6A or 6C 681 2 5 9 1 6 19 14 6b +, 6d + wciPa wciNa no
doi:10.1371/journal.pone.0060848.t003
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the fact that about 80% of all children in Germany are vaccinated
with PCV13, which contains both serotype 6A and 6B.
The levels of serotype 6C have been low in the pre-vaccination
period (0.0–1.5%), but gradually increased post-vaccination, up to
a level of 3.6% in 2011–2012. The levels indicate no herd
protection for serotype 6C from PCV7 childhood vaccination. A
possible herd protection effect from higher-valent vaccination has
also not been observed to date. The remaining level of serotype 6A
and the increase in serotype 6C among adults seem to indicate that
an eradication of these serotypes is not possible through herd
protection alone, and might need adult vaccination.
An increase of serotype 6C isolates, first among adults and later
in children, has been reported in Spain [21]. In the US, an
increase in 6C was observed after the introduction of vaccination
among both children and adults, even though levels of 6C
remained low [11]. In Germany, the increase in serotype 6C in
IPD among adults has so far remained without a concurrent
increase in IPD in children.
Table 4. MLSTs of serotype 6C isolates from IPD among German children and adults.
Serotype n= MLST aroE gdh gki recP spi xpt ddl
children
6C 9 1692 1 5 7 12 17 158 14
6C 2 600 5 10 9 43 13 1 14
6C 1 8632 5 10 9 43 13 506 14
6C 1 176 7 13 8 6 10 6 14
6C 1 681 2 5 9 1 6 19 14
6C 1 8633 2 10 378 18 27 1 31
adults
6C 11 1692 1 5 7 12 17 158 14
6C 2 473 7 25 4 4 15 20 28
6C 2 1390 10 13 1 43 98 1 20
6C 2 8613 10 25 12 1 15 20 28
6C 2 8633 2 10 378 18 27 1 31
6C 1 176 7 13 8 6 10 6 14
6C 1 207 10 8 30 5 6 1 9
6C 1 224 10 25 8 6 25 6 8
6C 1 367 2 22 4 18 27 4 8
6C 1 395 1 5 7 12 17 1 14
6C 1 460 5 7 4 10 10 1 27
6C 1 600 5 10 9 43 13 1 14
6C 1 667 8 13 14 4 14 4 14
6C 1 681 2 5 9 1 6 19 14
6C 1 1014 2 10 1 43 6 31 6
6C 1 1092 2 13 2 1 6 19 14
6C 1 1150 7 25 8 6 25 6 8
6C 1 1640 13 1 1 2 6 1 18
6C 1 1714 1 5 7 12 17 148 14
6C 1 2185 1 10 9 43 5 1 6
6C 1 2667 7 25 8 16 25 6 8
6C 1 3127 1 25 4 4 15 28 28
6C 1 4269 7 5 4 5 6 1 18
6C 1 8396 7 5 4 6 25 6 8
6C 1 8611 10 13 9 43 6 19 14
6C 1 8612 7 5 8 6 6 20 8
6C 1 8614 1 25 8 16 25 6 8
6C 1 8630 2 379 2 17 6 22 14
6C 1 8615 32 28 7 1 15 52 14
6C 1 8631 32 28 377 1 15 52 14
6C 1 8628 2 378 9 1 6 19 14
doi:10.1371/journal.pone.0060848.t004
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Serotype 6D appeared to be extremely rare and was found
among adult isolates only. All four isolates were from the post-
PCV7-vaccination period, and two were post-PCV10/13. Sero-
type 6D isolated from invasive pneumococcal disease was first
reported from Poland [22], where isolates were found both among
children and adults. Interestingly, two of these isolates were
ST948, an ST found in one of the German isolates as well. A
further invasive 6D isolate was reported from Finland, having
ST5163 [23]. In South Korea, 6D was found in four invasive
isolates from children (all ST3171) and in one isolate from an adult
patient (ST189) [24].
The INDEL was found in 46% of a subset of 95 6B isolates but
not among 47 tested 6A isolates. This differs from what was found
by Mavroidi et al. [7], who found INDEL frequencies of 20% in
6B and 2% in 6A.
The highest level of antibiotic resistance was found in serotype
6B isolates, followed by serotype 6A isolates, from both children
and adults. This was in accordance with reports for the pre-
vaccination period in many countries including the US, UK and
Spain [25–27]. Serotype 6C only showed antibiotic resistance
among adult isolates. One third of the resistant 6C isolates were
multi drug resistant. Similar findings about serotype 6C antibiotic
resistance were reported from Spain [28] and the US [29].
Serotype 6C isolates were found in connection with different
forms of IPD, including pneumonia, sepsis and meningitis. This
shows that serotype 6C is capable of causing a spectrum of IPD,
comparable to other members of serogroup 6, as was previously
reported [22–24].
The MLSTs found for the serotype 6C isolates in this study are,
for the larger part, common to sequence types found among
serogroup 6 isolates. Three of the four serotype 6D isolates
belonged to clonal complexes common to serogroup 6 isolates.
One 6D isolate (ST 8442) was not represented in the MLST
database and remained a singleton in the eBURST analysis.
Two serogroup 6 isolates could not be typed correctly as 6A/6C
or 6B/6D, respectively, using both factor sera as well as PCR
analysis. However, both isolates have MLSTs that are common in
serogroup 6. These isolates might represent as yet unknown
serogroup 6 subtypes, and are under further investigation.
In Germany the prevalence of serotype 6A and 6B in IPD both
among children and adults has diminished since the introduction
of childhood conjugate vaccination. However, serotype 6C and
possibly 6D are increasingly observed among IPD in adults. Future
surveillance will reveal whether a cross-protection effect from
higher-valent pneumococcal vaccination will reduce the preva-
lence of these serotypes.
Figure 3. eBURST snapshot of serogroup 6 isolates from IPD in children and adults in Germany. Serotypes are color coded. Circles are
proportional to the amount of isolates.
doi:10.1371/journal.pone.0060848.g003
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